Anti EX02 chimeric antigen receptor T cell therapy - Zeno Therapeutics
Alternative Names: EX02-CAR TLatest Information Update: 05 Mar 2024
At a glance
- Originator Zeno Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Jan 2024 Preclinical trials in Solid tumours in Singapore (Intraperitoneal), prior to January 2024 (NCT06196658)
- 17 Jan 2024 Preclinical trials in Solid tumours in Singapore (Intratumoural), prior to January 2024 (NCT06196658)
- 17 Jan 2024 Preclinical trials in Solid tumours in Singapore (IV), prior to January 2024 (NCT06196658)